Recently, Darini et al. [64] demonstrated that salubrinal potentiates the antitumor activity of trastuzumab in HER2+ breast cancer xenografts by increasing P21 and JNK1/2 activity, thus providing a robust experimental rationale for the therapeutic use of salubrinal in breast and gastric cancers. This evidence concerns the gene ERBB2 and breast carcinoma.